Medicare AdvantageCoverageMedium impact
MA08.082q, Efbemalenograstim alfa-vuxw (Ryzneuta®), Eflapegrastim-xnst (Rolvedon™), Pegfilgrastim (Neulasta®) and Related Biosimilars
Independence Blue Cross·Oncology, Hematology, Pharmacy·Pharmacy
Effective date
Jul 1, 2026
We identified it
Jul 2, 2026
Summary
This is a new Medicare Advantage policy effective July 1, 2026, establishing coverage and billing guidelines for granulocyte-colony stimulating factor (G-CSF) products including Ryzneuta® (efbemalenograstim alfa-vuxw), Rolvedon™ (eflapegrastim-xnst), Neulasta® (pegfilgrastim), and related biosimilars. The policy provides updated coverage criteria and billing requirements for these chemotherapy support medications.
Action Required
By June 30, 2026: Billing team must obtain and review the complete MA08.082q policy document from the source URL to identify specific HCPCS codes (likely J-codes for G-CSF products), prior authorization requirements, and coverage criteria. Update billing software, encounter forms, and provider documentation templates with the specific coverage rules and any new prior authorization workflows. Oncology, hematology, and chemotherapy administration staff should be trained on new requirements. Verify with the insurance carrier whether prior authorization is required before dispensing or administering these G-CSF products. Failure to comply with coverage criteria may result in claim denials or billing delays.